An international consortium led by SciLifeLab and KTH published a large‑scale proteomic atlas profiling ~9,000 blood samples across 59 diseases using Olink Explore/Explore HT platforms and made the dataset open for research. The study, published in Science, measured thousands of proteins and identified disease‑specific and pan‑disease signatures, offering a new resource for biomarker discovery and comparative diagnostics. Authors argue the pan‑disease design prevents false leads that are disease‑nonspecific and enables longitudinal tracking; the dataset includes a wellness cohort sampled six times over two years. The paper establishes a publicly accessible proteomic baseline, which biopharma and diagnostic developers can use to prioritize targets and refine specificity before costly clinical validation.